Grant: Operating Grant
McGill University
$371,344.00
From Rational Design To in vivo Evaluation of Dual Covalent Prolyl Oligopeptidase / Fibroblast Activation Protein Inhibitors as Potential Cancer Therapeutics.
EF 2013-14
Résumé
Proline oligopeptidase (POP), and fibroblast activation protein-alpha (FAP), are large homologous enzymes. POP has been a target for potential neurodegenerative diseases therapeutics. More recenlty, cancer cells were found to exhibit elevated levels of POP and our previous work has demonstrated that inhibitors can block the POP protease activity in various cancer cell lines while others have found that POP inhibition blocks cancer cell growth. Similarly, inhibition of FAP significantly affects tumor growth in vivo. In addition, FAP is absent from normal tissues making it a highly valuable target for selective therapies. Earlier this year, it was demonstrated that targeting both FAP and POP blocks stromal invasion and angiogenesis simultaneously, significantly altering tumor growth.
We will develop and apply novel approaches for the rational design of covalent POP/FAP dual inhibitors or combination of selective inhibitors by applying cutting-edge synthetic, computational, and biophysical techniques together with various biological assays. This research will generate potential cancer therapeutics as well as extensive knowledge and methods for the development of covalent drugs. In vivo evaluation of the most promising drug candidates will also be carried out.
Programme
Operating Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
304789
Name
Moitessier Nicolas R
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
From Rational Design To in vivo Evaluation of Dual Covalent Prolyl Oligopeptidase / Fibroblast Activation Protein Inhibitors as Potential Cancer Therapeutics.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$371,344
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Animal Models; Cancer Therapeutics; Computer-Aided Drug Design; Fibroblast Activation Protein; In Vivo Testing; Medicinal Chemistry; Nmr Spectroscopy; Organic Synthesis; Prolyl Oligopeptidase
Abstract
Proline oligopeptidase (POP), and fibroblast activation protein-alpha (FAP), are large homologous enzymes. POP has been a target for potential neurodegenerative diseases therapeutics. More recenlty, cancer cells were found to exhibit elevated levels of POP and our previous work has demonstrated that inhibitors can block the POP protease activity in various cancer cell lines while others have found that POP inhibition blocks cancer cell growth. Similarly, inhibition of FAP significantly affects tumor growth in vivo. In addition, FAP is absent from normal tissues making it a highly valuable target for selective therapies. Earlier this year, it was demonstrated that targeting both FAP and POP blocks stromal invasion and angiogenesis simultaneously, significantly altering tumor growth.
We will develop and apply novel approaches for the rational design of covalent POP/FAP dual inhibitors or combination of selective inhibitors by applying cutting-edge synthetic, computational, and biophysical techniques together with various biological assays. This research will generate potential cancer therapeutics as well as extensive knowledge and methods for the development of covalent drugs. In vivo evaluation of the most promising drug candidates will also be carried out.
Competitiondate
201403
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Moitessier, Nicolas R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $371,344~ $0~